Form 8-K Summary
Registrant: Flora Growth Corp., not Zerostack Corp. The filing reports an event dated November 15, 2023, under Item 5.02 concerning equity awards to officers and directors.
Business Context and Reporting Period
On November 10, 2023, after market close, Flora Growth granted 726,241 restricted stock awards (RSAs) under its 2022 Equity Compensation Plan. The Form 8-K was filed on November 15, 2023. The company’s common shares trade on the Nasdaq Capital Market under the symbol FLGC.
Equity Awards and Key Terms
| Participant | Role | RSAs | Vesting Date |
|---|---|---|---|
| Clifford Starke | CEO and Director | 327,851 | November 15, 2023 |
| Dany Vaiman | CFO | 149,024 | January 1, 2024 |
| Kevin Taylor | Chairman | 124,186 | January 1, 2024 |
| Edward Woo | Director | 74,512 | January 1, 2024 |
| Thomas Solomon | Director | 35,766 | November 15, 2023 |
Financial Metrics and Material Changes
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, financial guidance, or other operating metrics. It also does not provide a prior-period comparison. The principal disclosed change is the issuance of equity-based compensation to executive officers and directors.
Outlook, Risks, and Unusual Items
The filing does not provide management guidance or an operating outlook. The awards may result in equity compensation expense and dilution, but the filing text does not state the awards’ fair value, expense-recognition period, share price, or aggregate potential dilution.
Important Facts to Verify
- Confirm that Flora Growth Corp., rather than Zerostack Corp., is the intended registrant.
- Verify the terms, vesting conditions, and fair value of the 726,241 RSAs under the 2022 Equity Compensation Plan.
- Assess the potential dilution and equity compensation expense in subsequent financial statements.
- Confirm whether any additional restrictions, forfeiture provisions, or acceleration rights apply to the awards.